Navigation Links
Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
Date:12/7/2007

es Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are subject to risks and uncertainties that may cause actual future experience and results to differ materially from those discussed in these forward-looking statements. Important factors that might cause such a difference include, but are not limited to, costs related to the Merger, failure of AVANT's stockholders to approve the Merger; AVANT's or Celldex's inability to satisfy the conditions of the Merger; AVANT's inability to maintain its NASDAQ listing; the risk that AVANT's and Celldex's businesses will not be integrated successfully; the combined company's inability to further identify, develop and achieve commercial success for new products and technologies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that the combined company may be unable to successfully secure regulatory approval of and market its drug candidates; the risks associated with reliance on outside financing to meet capital requirements; risks associated with Celldex's new and uncertain technology; risks of the development of competing technologies; risks related to the combined company's ability to protect its proprietary technologies; risks related to patent-infringement claims; risks of new, changing and competitive technologies and regulations in the U.S. and internationally; and other events and factors disclosed previously and from time to time in AVANT's filings with the Securities and Exchange Commission, including AVANT's Annual Report on Form 10-K for the year ended December 31, 2006. The companies do not undertake any obligation to release publicly any revisions to such forward-looking statements to
'/>"/>
SOURCE Celldex Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... DIEGO and CARDIFF-BY-THE-SEA, Calif. ... Inc. (NASDAQ: SRNE ;  Sorrento), an ... associated pain, and Conkwest, Inc., a privately-held immuno-oncology ... Natural Killer (NK) cell-line based therapy, announced today ... agreement to jointly develop next generation CAR-TNK™ (pronounced ...
(Date:12/19/2014)... 18, 2014  Decision Resources Group finds that the ... will increase to a value of over ... by expansion in the large direct energy device market. ... increasingly adopted due to the advantages they offer and ... findings from Decision Resources Group,s coverage of the U.S. ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... University Medical Pharmaceuticals, which specializes in developing and distributing ... to the mass market, announced today that it has ... , Mr. Ten brings 28 years of ... luxury and consumer packaged goods industry. At University ...
... Inc., a company leading the scientific research of neurogenesis ... identify novel pathways for the treatment of central nervous ... Scolnick from the Broad Institute of MIT and Harvard ... to its scientific advisory board. The appointees join BrainCells, ...
Cached Medicine Technology:University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales 2University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales 3BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman 2BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman 3
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation ... and Whittier offices. The Hope for the Holidays Toy Drive ... and their families during the holiday season. This year, the ... children between both offices. This event continues to be successful ... service team, store managers and assistant managers came out and ...
(Date:12/20/2014)... Weddingshe.com has recently announced its new collection of ... special occasion dresses for the coming new year. ... dresses for global women. Now, all the models on ... 80% off. Among the new items, the model of ... is very popular. What’s more, Weddingshe.com also provides a ...
(Date:12/20/2014)... SATURDAY, Dec. 20, 2014 (HealthDay News) -- The holidays ... when they contend with fresh trees, scented candles and ... and on the decorations that have been packed away ... in my allergy and asthma patients," Dr. Rachna Shah, ... School of Medicine, said in Loyola news release. ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Atore, Inc, ... company just launched first birthday focused portal on December ... BIRTHDAY MESSAGE” launched in both US and Japan. , ... MESSAGE : http://merrybirthday.net/message/ , MERRY BIRTHDAY MESSAGE ... birthday around the world. , Features, Choose from thousands ...
(Date:12/20/2014)... The Twin Cities DI Day is recognized ... nation! Over 250 financial professionals come together each year ... industry, get motivated to protect their clients and to ... overcoming the challenges of disability. , On September 23rd, ... together to attend The 13th Annual Twin Cities DI ...
Breaking Medicine News(10 mins):Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3
... College at Dallas report that contact lenses, both ... materials are expected to reduce the possibility of ... available now. Based in part on these findings, ... hyper-oxygen transmissible contact lenses for 30-day continuous wear.// ...
... way to stop the hair loss associated with drug treatment ... alopecia (CIA), is a frequent side effect of cancer therapy ... time in their lives.// ,Currently, there is no effective ... way doctors can attempt to minimise hair loss is to ...
... have found the genetic mutation that is to blame ... many people.The breakthrough could lead to the development of drugs ... more than one in twelve people suffer from some form ... a history of problems such as panic disorders, agoraphobia and ...
... clues to the high failure rate of cloning and ... core of the nucleus.The discovery, announced at the annual ... Science in Washington, shows that DNA has an internal ... provides clues to how active genes and 'junk DNA' ...
... study, exercise can help older people avert a form ... standing up and walking an impossible one.Those who regularly ... lose abilities to perform activities of daily living. ... Texas, this report is the first to demonstrate that ...
... have developed a screening technique for persons suffering from ... investigations of skin lesions may allow doctors to identify ... particularly those of the colon. ,By looking ... in members of families with a history of HNPCC ...
Cached Medicine News:Health News:New contact lens materials 2Health News:Breakthrough in cancer therapy 2Health News:The anxiety gene, 2Health News:DNA and clones 2Health News:Arthritis risk reduced by exercise 2
... Produces up to 12 L/min of Type ... On Demand, The Super-Q Plus System is ... water which has been pretreated by reverse ... consistently produce ultrapure water quality which exceeds ...
... to 12 L/min of Type I ultrapure ... The Super-Q Plus System is designed to ... has been pretreated by reverse osmosis, distillation ... ultrapure water quality which exceeds Type I ...
... Water for Basic Laboratory Needs, Synergy systems ... flow rate from 1 to 1.2 L/min to ... Synergy 185 system incorporates a dual-wavelength UV lamp ... with low levels of organic contaminants (< 5 ...
... speed, stability and durability. Back-lighted Display. ... multiple units of measure, piece counting ... and GLP/GMP/ISO output including date and ... Built-in, motor-driven internal calibration mass for ...
Medicine Products: